^
Association details:
| Biomarker: | ALK C1156Y + ALK I1171T |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Patient-derived lung cancer organoids for the selection of therapeutic options in an ALK-rearranged tumor.
Published date:
05/19/2021
Excerpt:
A third liver biopsy for PDOs and NGS revealed acquired ALK C1156Y and I1171T mutations that confer resistance to crizotinib but sensitive to ceritinib, respectively.
DOI:
10.1200/JCO.2021.39.15_suppl.e21014
